FDA · Regulatory Safety Communication · 2026-07-23
Regulatory UpdateFDA safety communication: rare but serious hepatic events associated with an oral antifungal
Why it matters. Affects antifungal prescribing and monitoring you may oversee, especially amid rising Candida auris treatment.
Study design
- Design
- Postmarketing safety review
- Population
- Patients receiving the oral antifungal
Provenance
- Source
- FDA
- Source type
- regulatory
- Content analyzed
- regulatory doc
Evidence grading reflects the portion of the source actually analyzed. Always confirm against the original before acting.
Your read
Post your interpretation for colleagues. Every post stays anchored to this source, no empty-box updates.
Sign in to post your read of this evidence.